139 related articles for article (PubMed ID: 20955619)
1. Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
Levin RD; Daehler M; Grutsch JF; Hall JL; Gupta D; Lis CG
BMC Cancer; 2010 Oct; 10():565. PubMed ID: 20955619
[TBL] [Abstract][Full Text] [Related]
2. Romiplostim for management of chemotherapy-induced thrombocytopenia.
Parameswaran R; Lunning M; Mantha S; Devlin S; Hamilton A; Schwartz G; Soff G
Support Care Cancer; 2014 May; 22(5):1217-22. PubMed ID: 24414994
[TBL] [Abstract][Full Text] [Related]
3. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
[TBL] [Abstract][Full Text] [Related]
4. [Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)].
Consensus Committee of Chemotherapy Induced Thrombocytopenia, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):714-720. PubMed ID: 30293399
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for intervention.
Degliuomini MD; Armstrong K; Mauguen A; Slotkin EK; Roberts SS; Dunkel IJ; Clouser M; Ortiz MV; Soff GA
Pediatr Blood Cancer; 2022 Oct; 69(10):e29776. PubMed ID: 35593014
[TBL] [Abstract][Full Text] [Related]
6. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
7. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
Basser RL; Underhill C; Davis I; Green MD; Cebon J; Zalcberg J; MacMillan J; Cohen B; Marty J; Fox RM; Begley CG
J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133
[TBL] [Abstract][Full Text] [Related]
9. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.
Vadhan-Raj S; Patel S; Bueso-Ramos C; Folloder J; Papadopolous N; Burgess A; Broemeling LD; Broxmeyer HE; Benjamin RS
J Clin Oncol; 2003 Aug; 21(16):3158-67. PubMed ID: 12915607
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
[TBL] [Abstract][Full Text] [Related]
11. Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O')-diammine platinum (II) (NSC 375101D).
Sasaki Y; Fukuda M; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Yamada K; Kojima A; Nakagawa K
Jpn J Cancer Res; 1990 Feb; 81(2):196-200. PubMed ID: 2110134
[TBL] [Abstract][Full Text] [Related]
12. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
[TBL] [Abstract][Full Text] [Related]
13. Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy.
Wu S; Zhang Y; Xu L; Dai Y; Teng Y; Ma S; Ho SH; Kim JM; Yu SS; Kim S; Song S
Support Care Cancer; 2012 Aug; 20(8):1875-84. PubMed ID: 22041866
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
Sun XF; Guan ZZ; Huang H; Zhou QH; Yi C; Zhang LJ; Zhu J; Li R; Zhou J; Zhang M; Guo Y
Ai Zheng; 2002 Aug; 21(8):892-5. PubMed ID: 12478901
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.
D'Hondt V; Weynants P; Humblet Y; Guillaume T; Canon JL; Beauduin M; Duprez P; Longueville J; Müll R; Chatelain C
J Clin Oncol; 1993 Nov; 11(11):2063-71. PubMed ID: 8229120
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
[TBL] [Abstract][Full Text] [Related]
18. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
